"Challenges and Competition in the Weight Loss Drug Market"
TL;DR Summary
Demand for weight loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound is outstripping supply, leading to intermittent shortages and limited availability. Both companies are making efforts to increase production capacity, with Novo Nordisk doubling its supply of lower-dose Wegovy and Eli Lilly doubling production capacity for its incretin drugs. Novo Nordisk's parent company's acquisition of Catalent and investments in new production facilities, along with Eli Lilly's plans to launch drugs in alternative delivery devices and develop oral weight loss drugs, aim to address supply constraints in the future.
Topics:business#eli-lilly#health#novo-nordisk#obesity-medications#supply-shortages#weight-loss-drugs
- Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that CNBC
- Catalent's Indiana filling plant in hot water with the FDA yet again FiercePharma
- EU watchdog looking into impact on drug availability from Catalent-Novo deal Reuters
- Makers of Ozempic, Mounjaro race to meet demand for weight-loss drugs The Washington Post
- Novo Catalent deal to shake up CGT space - BioProcess Insider BioProcess Insider
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
6 min
vs 7 min read
Condensed
93%
1,368 → 90 words
Want the full story? Read the original article
Read on CNBC